Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 10, 2023

CLINICAL TRIALS PROFILE FOR INJECTAFER

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

All Clinical Trials for Injectafer

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00994318 ↗	Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)	Completed	American Regent, Inc.	Phase 3	2009-12-01	Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
NCT00994318 ↗	Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)	Completed	ICON Clinical Research	Phase 3	2009-12-01	Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
NCT00994318 ↗	Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)	Completed	Luitpold Pharmaceuticals	Phase 3	2009-12-01	Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
NCT00994318 ↗	Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)	Completed	Vifor Inc.	Phase 3	2009-12-01	Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Injectafer

Condition Name

Chart
Table

Condition Name for Injectafer
Intervention	Trials
Iron Deficiency Anemia	7
Iron Deficiency Anaemia	3
Iron-deficiency	3
Heart Failure	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Injectafer
Intervention	Trials
Anemia, Iron-Deficiency	18
Anemia	13
Deficiency Diseases	10
Heart Failure	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Injectafer

Trials by Country

Map
Table

Trials by Country for Injectafer
Location	Trials
United States	104
Canada	8
Australia	7
Poland	4
Georgia	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Injectafer
Location	Trials
Texas	7
Florida	7
Pennsylvania	6
North Carolina	5
New York	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Injectafer

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Injectafer
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	8
Phase 2	7
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Injectafer
Clinical Trial Phase	Trials
Completed	14
Recruiting	3
Terminated	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Injectafer

Sponsor Name

Chart
Table

Sponsor Name for Injectafer
Sponsor	Trials
American Regent, Inc.	13
Luitpold Pharmaceuticals	12
Pharmacosmos A/S	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Injectafer
Sponsor	Trials
Industry	34
Other	9
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck

Moodys

AstraZeneca

Mallinckrodt

Harvard Business School

Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.